EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR

Duangjai Todsaporn, Alexander Zubenko, Victor G Kartsev, Panupong Mahalapbutr iD, Athina Geronikaki, Samvel N Sirakanyan, Lyudmila N Divaeva, Victoria Chekrisheva, Ilkay Yildiz, Kiattawee Choowongkomon iD, Thanyada Rungrotmongkol iD

The Journal of Physical Chemistry B · 2024

DOI: 10.1021/acs.jpcb.4c06246 ↗

At a glance

Journal article in The Journal of Physical Chemistry B, 2024. Written by Duangjai Todsaporn and 10 co-authors. Institution: Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok …. Major MEDLINE topics: ErbB Receptors, Pyridines, Protein Kinase Inhibitors, Molecular Dynamics Simulation. Cited 13 times so far (Crossref); 52 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Office of National Higher Education Science Research and Innovation Policy Council, Chulalongkorn University, Fundamental Scientific Research of the State Academies of Sciences.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The treatment of patients with nonsmall cell lung cancer (NSCLC) using epidermal growth factor receptor (EGFR) inhibitors is complicated by drug-sensitive activating L858R/T790M and L858R/T790M/C797S mutations. To overcome drug resistance, a series of furopyridine (PD) compounds were virtually screened to identify potent EGFR inhibitors using molecular docking and molecular dynamics (MD) simulations based on the solvated interaction energy (SIE) method. Several PD compounds identified from virtual screening demonstrated the potential to suppress both wild-type and mutant forms of EGFR, with IC50 values in the nanomolar range. Among these, PD18 and PD56 exhibited highly potent inhibitory activity against both wild-type and mutant forms of EGFR, surpassing the efficacy of known drugs. Additionally, both PD compounds were cytotoxic to NSCLC cell lines (A549 and H1975) while being nontoxic to normal cell lines (Vero). The interaction mechanisms of both PD compounds complexed with wild-type and mutant forms of EGFR were elucidated through 500 ns molecular dynamics simulations. The predicted binding affinity from molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) correlated well with the experimental binding affinity derived from IC50 values. Furthermore, it was observed that van der Waals interactions, rather than electrostatic interactions, played a significant role in interacting with EGFR's active site. The strong inhibitory activity against EGFR was attributed to two key residues, M793 and S797, via hydrogen bonding, corresponding with lower solvent accessibility and a higher number of atomic contacts. Therefore, these potent compounds could be developed as promising drugs targeting both wild-type and mutant EGFR for the treatment of NSCLC.

Subjects

MeSH terms (MEDLINE)

ErbB ReceptorsPyridinesProtein Kinase InhibitorsMolecular Dynamics SimulationMolecular Docking SimulationMutationHumansAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorFuransMolecular StructureLung Neoplasms

Substances

ErbB ReceptorsPyridinesProtein Kinase InhibitorsEGFR protein, humanAntineoplastic AgentsFurans

Authors and institutions

  • Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
  • North-Caucasian Zonal Research Veterinary Institute, 346406 Novocherkassk, Russia.
  • InterBioScreen, 85355 Moscow, Russia.
  • Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
  • Department of Pharmaceutical Chemistry, School of Health, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
  • The Scientific Technological Center of Organic and Pharmaceutical Chemistry, Armenian Academy of Science, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Avenue Azatutyan 26, Yerevan 0014, Armenia.

ORCID profiles: Panupong Mahalapbutr, Kiattawee Choowongkomon, Thanyada Rungrotmongkol

Funding

  • Office of National Higher Education Science Research and Innovation Policy Council
  • Chulalongkorn University
  • Fundamental Scientific Research of the State Academies of Sciences
  • Ministry of Science and Higher Education of the Russian Federation

Cite

APA

Todsaporn, D., Zubenko, A., Kartsev, V. G., Mahalapbutr, P., Geronikaki, A., Sirakanyan, S. N., Divaeva, L. N., Chekrisheva, V., Yildiz, I., Choowongkomon, K., & Rungrotmongkol, T. (2024). Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.4c06246

Vancouver

Todsaporn D, Zubenko A, Kartsev VG, Mahalapbutr P, Geronikaki A, Sirakanyan SN, et al. Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR. The Journal of Physical Chemistry B. 2024. doi:10.1021/acs.jpcb.4c06246

BibTeX
@article{Todsaporn2024,
  author = {Todsaporn, Duangjai and Zubenko, Alexander and Kartsev, Victor G and Mahalapbutr, Panupong and Geronikaki, Athina and Sirakanyan, Samvel N and Divaeva, Lyudmila N and Chekrisheva, Victoria and Yildiz, Ilkay and Choowongkomon, Kiattawee and Rungrotmongkol, Thanyada},
  title = {Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR},
  journal = {The Journal of Physical Chemistry B},
  year = {2024},
  doi = {10.1021/acs.jpcb.4c06246}
}
Start for free →